The antibody produces strong labeling of VAChT at dilutions of 1/200 - 1/400 using indirect immunofluorescence and at dilutions of 1/3,000 - 1/5,000 using biotin-streptavidin/HRP technique in rat basal forebrain.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Goat
Species Reactivity:
Human, Mouse, Rat
Immunogen:
Rat VAChT 511-530
Applications:
Electron Microscopy; Immunocytochemistry; Immunofluorescence; Immunohistochemistry.
Solute carrier family 18, member 3;solute carrier family 18 (vesicular monoamine) member 3; solute carrier family 18 (vesicular acetylcholine), member 3;rVAT; VACht
Additional Info:
The VAT Antibody produces strong labeling of VAChT at a dilution of 1/3,000 - 1/5,000 using biotin-streptavidin/HRP technique in rat basal forebrain.
Gene Symbol:
Slc18a3,60422
NCBI Gene Aliases:
Solute carrier family 18, member 3; member 3;rVAT; VACht
The 5-HIAA antibody was raised to 5-HIAA coupled to BSA with paraformaldehyde. The antibody produces moderate labeling of raphe neurons in normal rat. In rats whose serotonergic system has been activated, staining intensity is increased to a maximum label. Recommended dilutions of the antiserum are 1/200-1/400 for indirect immunofluorescence and 1/4000-1/8000 for biotin-streptavidin/HRP technique. The specificity of the antiserum was evaluated using a model system of gelatin-indole plugs by a method similar to published procedures (Schipper and Tilders, 1983). Results showed that the 5-HIAA antibody dose dependently stained 5-HIAA but did not stain any concentration of 5-HT or 5-HTP. The antiserum was also tested by pre-adsorption at 25 µg/mL with various BSA conjugates. While pre-adsorption with 5-HIAA conjugate completely eliminates immunolabeling, pre-adsorption with conjugates of 5-HT,5-HTP and dopamine had no effect on staining intensity or distribution of stain.
The Mu Opioid Receptor antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat caudate putamen and spinal cord (dorsal horn) using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/6000 - 1/10000 in PBS/0.3% Triton X-100 - Biotin/avidin-HRP Technique. Preadsorption with MOR peptide (384-398) at 10 µg/ml completely eliminates labeling. The specificity of the antiserum was determined by immunolabeling of transfected cells, Western Blot analysis and immunoisolation studies.
The rabbit antibody for Glucagon-like Protein Receptor is generated for acetyl 65-88 amide sequence targeting rat and human proteins, but not mouse. The peptide was synthesized and cross-linked to keyhole limpet hemocyanin via sulfolink coupling. The antibody is provided as 100 µL of affinity purified serum containing 1% BSA.
Produced by Dr. Mark Brownfield, the peptide sequence encoding the rat GLP2R was retrieved from the NCBI protein database and evaluated using GeneRunner software to generate antigen candidates for antibody production. Antibody was generated in rabbits and purified by affinity chromatography against the antigenic peptide. The specificity of the antibody was confirmed by Western blotting and by immunoabsorption controls is the immunohistochemistry procedure (see Nelson et al, Endocrinology 148(5)1954-1962, 2007.
The antiserum demonstrates significant labeling of enteroendocrine cells in the intestinal epithelium, as well as cell bodies of vagal afferents in nodose ganglia of the parasympathetic nervous system. Immunolabeling of Western blot revealed a band of approximately 66 kDa in human and rat tissue.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Liquid
Host Animal:
Rabbit
Species Reactivity:
Rat
Immunogen:
Glucagon-like peptide 2 receptor (GLP2R) for acetyl 65-88 amide sequence targeting rat and human proteins, but not mouse.
The rabbit antibody for Glucagon-like Protein Receptor is generated for acetyl 65-88 amide sequence targeting rat and human proteins, but not mouse. The peptide was synthesized and cross-linked to keyhole limpet hemocyanin via sulfolink coupling.
The CGRP Antibody was raised to rat alpha-CGRP coupled to bovine thyroglobulin with glutaraldehyde. The antibody has a proven fluorescein staining at a 1/100-1/200 dilution and a strong Biotin-Streptadvidin/HRP staining at a 1/2000-1/4000 dilution in rat amygdala, and spinal cord. The specificity of the antiserum was evaluated by soluble pre-adsorption with the peptides in question at a final concentration of 10-5M. CGRP immunolabeling was completely abolished by pre-adsorption with rat α -CGRP and partially eliminated by pre-adsorption with rat -CGRP. Pre-adsorption with the following peptides resulted in no loss of immunostaining: rat amylin, rat adrenomedulin, calcitonin, neurotensin, somatostatin, substance P, leucine enkephalin, methionine enkephalin, VIP, CCK-8, vasopressin and neuropeptide Y.
The Tyrosine Hydroxylase antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat catecholamine neuron systems using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions for these methods are provided below. This antibody does not cross react with dihydropterdine reductase, dopamine-B-hydroxylase, phenylethanolamine-N-methyltransferase, phenylalanine hydroxylase or tryptophan hydroxylase using Western blot methods.
Neuropeptide Y (NPY) is a member of a regulatory peptide family and has a marked sequence homology with pancreatic polypeptide (PP) and peptide YY (PYY), which are other members of the family. In the rat central nervous system, immunohistochemistry has found NPY-like cell bodies in the cortex, caudate-putamen, hypothalamus (arcuate nucleus), hippocampus, anterior olfactory bulb, nucleus accumbens, amygdaloid complex and periaqueductal grey. NPY-like fibers and terminals are detected in high numbers in the bed nucleus of the stria terminalis, the peri- and paraventricular regions of the hypothalamus and thalamus and in discrete hypothalamic nuclei, particularly the suprachiasmatic nucleus. It has been used to detect NPY in a wide range of species including rat, mouse, human (1-7), fish, cat, bird, guinea pig, zebrafish, squirrels, frog, and newt.
Histamine is located in mast cells, endocrine cells of the gut, blood cells and in some cells of the peripheral and central nervous system. Histamine is a potent vasodilator when secreted by mast cells found in various tissues as a result of allergic hypersensitivity or inflammation. In the central nervous system, Histamine is putative neurotransmitter. In the brain, its highest content has been found in the hypothalamus and in certain areas of the mesencephalon. The Histamine antiserum has a sensitivity level capable of detecting the low level Histamine contents of the brain. The Histamine antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS/0.3% Triton X-100 Cy3 Technique and 1/4000-1/6000 in PBS/0.3% Triton X-100 biotin/avidin-HRP Technique . All staining is blocked by preabsorption of the antiserum with Histamine conjugate. Cross reactivity experiments indicate no cross reactivity with L-histidine or L-histidine containing peptides such as LH-RH.
The GHRF (Growth Hormone Releasing Factor) Antibody was raised to rat hypothalamic GHRF (1-43). The antibody produces strong labeling of GHRH at dilutions of 1/200-1/400 using indirect immunofluorescence and at dilutions of 1/2,000 - 1/4,000 using biotin/streptavidin HRP in rat hypothalamus (median eminence). Cross reactivity of GHRF antiserum was examined using the paper spot technique of Larsson (1981). Using 2 µL, 100 pmole amounts, the following substances did not react with rat GHRF antisera diluted 1/500 using the PAP labeling method: glucagon, gastric inhibitory peptide, secretin, vasoactive intestinal peptide, peptide histidine isoleucine, pancreatic polypeptide (human or rat), human GHRF, somatostatin, insulin, ACTH, motilin, cholecystokinin octapeptide, substance P, molluscan cardioexcitatiory peptide, gastrin 34, and serotonin. GHRF antiserum had a very good reactivity using rat GHRF at 2 µL, 100 pmole amounts.
The antibody has a proven strong indirect immunofluorescence at 1/400 - 1/800 and 4+ biotin-streptavidin/HRP staining at a 1/2000 - 1/4000 dilution in rat brainstem, cerebellum and adrenal medulla. Using Western blot of purified DBH the antiserum detects a triplet at approximately 72-74 kD.
This antibody has been shown to react strongly with human GFAP as well as with GFAP from rat, mouse, guinea pig, hamster, kangaroo, sheep, cat and monkey. Excellent staining results were obtained when rabbit anti-glial fibrillary acidic protein serum was tested.
The gamma amino butyric acid antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat thalamus and cerebellum using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/15,000- 1/20,000 in PBS /0.3% Triton X-100 - biotin/avidin-HRP technique. The specificity of the antiserum for GABA was evaluated using a competitive inhibition ELISA. While conjugates of GABA completely eliminate labeling, a 1000 fold excess of the following conjugates could not inhibit the antiserums ability to bind GABA conjugate: glutamate, aspartate, beta alanine, tyrosine, taurine, glycine and alanine.
The ImmunoStar gamma amino butyric acid antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat thalamus and cerebellum using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/15,000- 1/20,000 in PBS /0.3% Triton X-100 - biotin/avidin-HRP technique. The specificity of the antiserum for GABA was evaluated using a competitive inhibition ELISA. While conjugates of GABA completely eliminate labeling, a 1000 fold excess of the following conjugates could not inhibit the antiserums ability to bind GABA conjugate: glutamate, aspartate, beta alanine, tyrosine, taurine, glycine and alanine.
The ImmunoStar VIAAT antiserum was quality control tested using standard immunohistochemical methods in rat brain and spinal cord using biotin/avidin-HRP techniques.Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with an excess of rat VIAAT peptide residues 511-525. Western blot analysis of immunoprecipitated rat brain homogenates demonstrates a dense immunoreactive band of approximately 57 kD and a minor band of approximately 36 kD.
The FMRF-Amide antiserum was quality control tested using standard histochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/400 - 1/800 in PBS/0.3% Triton X-100 -Cy3 Technique and 1/1,000 - 1/2,000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. Staining is completely eliminated by pretreatment of the diluted antibody with 100 µg/mL of FMRF-Amide.
The antibody has a proven strong immunofluorescent staining at a 1/200-1/400 dilution, and a 4+ Biotin-Streptavidin/HRP staining at a 1/500-1/1000 dilution, in rat adrenal medulla and rat stomach.
The CRF Antibody was raised to synthetic ovine CRF. The ImmunoStar serotonin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat median eminence using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/200 - 1/400 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/1000 - 1/2000 in PBS/0.3% Triton X-100 - Biotin/Avidin-HRP Technique. Immuno-labeling is completely abolished by preadsorption with synthetic CRF at 100 ug per mL of diluted antibody.
The 5-HT BSA/Conjugate Control was prepared by cross-linking 5-HT creatinine sulfate complex to BSA with paraformaldehyde. Pre-adsorption of Serotonin antisera, diluted according to the antibody specification sheet, with 20 µg/ml Serotonin/BSA conjugate following the instructions below provides complete blockage of Serotonin immunolabeling. The conjugate is provided as 50 µg of lyophilized Serotonin creatinine sulfate coupled to BSA with paraformaldehyde.
The 5-HT Rabbit Antibody was raised against serotonin coupled to BSA with paraformaldehyde. The ImmunoStar serotonin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus, raphe nuclei and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/1,000-1/2,000 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/20,000-1/40,000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. Staining is completely eliminated by pretreatment of the diluted antibody with 25 ug of serotonin/BSA. Cross reactivity of Serotonin antisera was examined. With 5µg, 10µg and 25µg amounts the following substances did not react with Serotonin antisera diluted 1/20,000 using the Bn-SA/HRP labeling method: 5-hydroxytryptophan, 5-hydroxyindole -3- acetic acid, and dopamine.
The 5-HT Goat Rabbit Antibody was raised against serotonin coupled to BSA with paraformaldehyde. The ImmunoStar serotonin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/400 - 1/800 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/5000 - 1/10,000 in PBS/0.3% Triton X-100 - Bn/Av-HRP Technique. Staining is completely eliminated by pretreatment of the diluted antibody with 100 µg of serotonin/BSA conjugate.
The CCK-8 Antibody was raised to sulphated CCK-8 (26-33) coupled to bovine thyroglobulin with glutaraldehyde. The antibody has a proven strong indirect immunofluorescent staining at a 1/100-1/200 dilution and a strong Biotin-Streptavidin/HRP immunostaining at a 1/500-1/1000 dilution in rat hypothalamus and spinal cord. The specificity of the antiserum was examined by soluble pre-adsorption with the peptides in question at a final concentration of 10-6M CCK-8 immunolabeling was completely abolished by pre-adsorption with CCK-8, gastrin 17 and gastrin 34. Pre-adsorption with the following peptides resulted in no reduction of immunostaining: α-CGRP, -CGRP, neurotensin, somatostatin, substance P, leucine enkephalin, methionine enkephalin, VIP, neuropeptide Y, gastric inhibitory polypeptide, bombesin, glucagon, peptide YY, and FMRF amide.
The antibody has a proven strong fluorescent staining at a 1/200-1/400 dilution and a strong Biotin-Streptavidin/HRP staining at a 1/4000-1/6000 dilution in rat amygdala, cortex, and suprachiasmatic nucleus. The specificity of the antiserum was examined by soluble pre-adsorption with the peptides in question at a final concentration of 10-5 M. VIP immunolabeling was completely abolished by pre-adsorption with VIP. Pre-adsorption with the following peptides resulted in no reduction of immunostaining: Secretin, gastric inhibitory polypeptide, somatostatin, glucagon, insulin, ACTH, gastrin 34, FMRF-amide, rat GHRF, human GHRF, peptide histidine isoleucine 27, rat pancreatic polypeptide, motilin, peptide YY, substance P, neuropeptide Y, and CGRP. The histochemical antibody for VIP is generated in a rabbit against porcine VIP conjugated to bovine thyroglobulin with carbodiimide. The antibody is provided as 100 µL of lyophilized whole serum, and 0.09% sodium azide.
The Glucagon Antibody was raised to glucagon coupled to bovine thyroglobulin with glutaraldehyde. The antibody has a proven strong Biotin-Streptavidin/HRP immunostaining at a 1/500-1/1000 dilution in human pancreatic islets. Staining is completely eliminated by pretreatment of the diluted antibody in an excess of glucagon. Preadsorption of the diluted antibody with an excess of the following substances had no effect on glucagon labeling: secretin, vasoactive intestinal peptide, peptide histidine isoleucine-27, gastric inhibitory polypeptide, rat and human growth hormone releasing hormone and somatostatin.
The antibody produces a strong postive labeling of LHRH at dilutions of 1/200-1/400 using indirect immunofluorescence and at dilutions of 1/2,000 - 1,4,000 using biotin-streptavidin/HRP in rat hypothalamus (median eminence). Optimal dilution will vary depending upon fixation, labeling technique and/or detection system; therefore, a dilution series is recommended. Staining is completely eliminated by pretreatment of the diluted antibody with 5 µg of LHRH per mL of diluted antiserum.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
